1. Immunogenicity, reactogenicity and safety of the human rotavirus vaccine RIX4414 (Rotarix) oral suspension (liquid formulation) when co-administered with expanded program on immunization (EPI) vaccines in Vietnam and the Philippines in 2006-2007;Anh;Vaccine,2011
2. GlaxoSmithKline[109216-063] A phase II, randomized, double-blind, placebo-controlled study to evaluate the immunogenicity, reactogenicity and safety of two doses of GlaxoSmithKline (GSK) Biologicals’ oral live attenuated human rotavirus (HRV) liquid vaccine, when given to healthy infants, in Philippines ctr.gsk.co.uk/Summary/Vaccine_Rotavirus/II_109216.pdf 2008
3. NCT00432380 Immunogenicity and safety of two doses of GlaxoSmithKline (GSK) Biologicals' oral live attenuated human rotavirus (HRV) liquid vaccine (GSK 357941A) in healthy infants clinicaltrials.gov/show/NCT00432380
4. Immunogenicity, reactogenicity and safety of the human rotavirus vaccine RIX4414 (Rotarix) oral suspension (liquid formulation) when co-administered with expanded program on immunization (EPI) vaccines in Vietnam and the Philippines in 2006-2007;Anh;Vaccine,2011
5. Anh DD Thiem VD Hutagalung Y Bock HL Suryakiran P Delem A Immunogenicity, Reactogenicity and Safety of the Oral Live Attenuated Human Rotavirus VaccineRIX4414(RotarixTM) Oral Suspension (Liquid Formulation) in Vietnamese Infants 13th International Congress on Infectious Diseases Abstracts, Poster Presentations 2008